Chemistry:Solangepras

From HandWiki

Solangepras (INN; developmental code name CVN-424), or solengepras (USAN), is an inverse agonist of the orphan G protein-coupled receptor 6 (GPR6) which is under development for the treatment of Parkinson's disease.[1][2][3][4] It is a small molecule and is taken by mouth.[1][4] Solangepras produces hyperlocomotion and reverses haloperidol-induced catalepsy in rodents.[4] It is being developed by Cerevance.[1][2] As of October 2024, solangepras is in phase 3 clinical trials.[1][2]

References

  1. ↑ 1.0 1.1 1.2 1.3 "Solengepras". 21 October 2024. https://adisinsight.springer.com/drugs/800052918. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on CVN-424 with Synapse". 5 February 2025. https://synapse.patsnap.com/drug/9753f17fb4234ec5a7934dace6dc6c8e. 
  3. ↑ "Experimental Therapeutics in Parkinson's Disease". Neurologic Clinics 43 (2): 399–426. 2025. doi:10.1016/j.ncl.2024.12.013. PMID 40185528. 
  4. ↑ 4.0 4.1 4.2 "Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease". The Journal of Pharmacology and Experimental Therapeutics 377 (3): 407–416. June 2021. doi:10.1124/jpet.120.000438. PMID 33795395. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Solangepras&oldid=4037780"